In this episode of #AskDrDurie, IMF Chairman of Board Dr. Brian G.M. Durie discusses the progress being made with monoclonal antibodies being used to treat myeloma. He highlights three specific ones (daratumumab, Sanofi’s SAR compound, and elotuzumab) and discusses why each is promising.

Previous Post
If stringent complete remission is achieved, is maintenance therapy still required?
Next Post
Does pomalidomide work on a myeloma patient that has not had a response with other iMiDs?

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.